NASDAQ:CSTL Castle Biosciences (CSTL) Stock Forecast, Price & News $11.37 -11.36 (-49.98%) (As of 03:16 PM ET) Add Compare Share Share Today's Range$9.26▼$17.8750-Day Range$21.05▼$26.0052-Week Range$9.26▼$36.10Volume7.63 million shsAverage Volume225,717 shsMarket Capitalization$303.47 millionP/E RatioN/ADividend YieldN/APrice Target$44.67 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Castle Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside237.0% Upside$40.57 Price TargetShort InterestHealthy3.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 14 Articles This WeekInsider TradingSelling Shares$1.01 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.60) to ($2.23) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.42 out of 5 starsMedical Sector229th out of 980 stocksMedical Laboratories Industry6th out of 22 stocks 3.5 Analyst's Opinion Consensus RatingCastle Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $40.57, Castle Biosciences has a forecasted upside of 237.0% from its current price of $12.04.Amount of Analyst CoverageCastle Biosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.29% of the outstanding shares of Castle Biosciences have been sold short.Short Interest Ratio / Days to CoverCastle Biosciences has a short interest ratio ("days to cover") of 6.Change versus previous monthShort interest in Castle Biosciences has recently decreased by 10.98%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCastle Biosciences does not currently pay a dividend.Dividend GrowthCastle Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CSTL. Previous Next 2.2 News and Social Media Coverage News SentimentCastle Biosciences has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Castle Biosciences this week, compared to 3 articles on an average week.Search Interest3 people have searched for CSTL on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Castle Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Castle Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,008,684.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Castle Biosciences is held by insiders.Percentage Held by Institutions82.43% of the stock of Castle Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Castle Biosciences are expected to grow in the coming year, from ($3.60) to ($2.23) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Castle Biosciences is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Castle Biosciences is -4.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCastle Biosciences has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Castle Biosciences (NASDAQ:CSTL) StockCastle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.Read More Receive CSTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Castle Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Stock News HeadlinesJune 5, 2023 | msn.comLake Street Maintains Castle Biosciences (CSTL) Buy RecommendationJune 5, 2023 | americanbankingnews.comLake Street Capital Trims Castle Biosciences (NASDAQ:CSTL) Target Price to $32.00June 5, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. June 5, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Castle Biosciences (CSTL), Day One Biopharmaceuticals (DAWN) and Replimune Group (REPL)June 5, 2023 | finance.yahoo.comFramework Incorporating DecisionDx®-SCC Test Results into Clinical Decision-Making for Patients with High-Risk Cutaneous Squamous Cell Carcinoma Published in Clinical, Cosmetic and Investigational DermatologyJune 5, 2023 | americanbankingnews.comCastle Biosciences (NASDAQ:CSTL) Price Target Lowered to $25.00 at Robert W. BairdJune 3, 2023 | finance.yahoo.comCastle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual MeetingJune 2, 2023 | finance.yahoo.comWhy Shares of Castle Biosciences Slumped This WeekJune 5, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. June 2, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Castle Biosciences (CSTL), Karuna Therapeutics (KRTX)May 31, 2023 | finance.yahoo.comIDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive DisorderMay 30, 2023 | finance.yahoo.comCastle Biosciences Celebrates Skin Cancer Awareness MonthMay 26, 2023 | businesswire.comCastle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as “Posters of Distinction” by the American Gastroenterological Association (AGA ...May 26, 2023 | finance.yahoo.comCastle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as "Posters of Distinction" by the American Gastroenterological Association (AGA) Institute CouncilMay 25, 2023 | finance.yahoo.comFirst look: Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova PlaceMay 24, 2023 | finance.yahoo.comCastle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova PlaceMay 20, 2023 | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $36,066.10 in StockMay 15, 2023 | finance.yahoo.comCastle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence InnovationMay 11, 2023 | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $60,418.88 in StockMay 11, 2023 | americanbankingnews.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $382,676.67 in StockMay 9, 2023 | americanbankingnews.comSVB Leerink Weighs in on Castle Biosciences, Inc.'s Q2 2023 Earnings (NASDAQ:CSTL)May 5, 2023 | msn.comStephens & Co. Reiterates Castle Biosciences (CSTL) Overweight RecommendationMay 5, 2023 | msn.comKeybanc Maintains Castle Biosciences (CSTL) Overweight RecommendationMay 5, 2023 | finance.yahoo.comCastle Biosciences First Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsMay 4, 2023 | markets.businessinsider.comAnalyst Expectations for Castle Biosciences's FutureMay 4, 2023 | americanbankingnews.comCastle Biosciences (NASDAQ:CSTL) Price Target Cut to $35.00May 3, 2023 | msn.comCastle Biosciences GAAP EPS of -$1.10 misses by $0.21, revenue of $42.04M beats by $4.66MSee More Headlines CSTL Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CSTL Company Calendar Last Earnings5/03/2023Today6/05/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CSTL CUSIPN/A CIK1447362 Webcastlebiosciences.com Phone(866) 788-9007FaxN/AEmployees342Year FoundedN/APrice Target and Rating Average Stock Price Forecast$40.57 High Stock Price Forecast$54.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+271.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,140,000.00 Net Margins-47.11% Pretax Margin-48.35% Return on Equity-17.74% Return on Assets-16.02% Debt Debt-to-Equity RatioN/A Current Ratio8.99 Quick Ratio8.84 Sales & Book Value Annual Sales$137.04 million Price / Sales2.34 Cash FlowN/A Price / Cash FlowN/A Book Value$15.15 per share Price / Book0.79Miscellaneous Outstanding Shares26,690,000Free Float24,636,000Market Cap$320.81 million OptionableNot Optionable Beta1.01 Key ExecutivesDerek J. MaetzoldPresident, Chief Executive Officer & DirectorKristen M. OelschlagerChief Operating OfficerFranklin Michael StokesChief Financial OfficerRobert W. CookSenior Vice President-Research & DevelopmentMatthew GoldbergMedical DirectorKey CompetitorsProgenityNASDAQ:PROGCareDxNASDAQ:CDNAViridian TherapeuticsNASDAQ:VRDNInvitaeNYSE:NVTACelcuityNASDAQ:CELCView All CompetitorsInsiders & InstitutionsLegato Capital Management LLCBought 9,038 shares on 5/25/2023Ownership: 0.103%Ameriprise Financial Inc.Bought 3,670 shares on 5/22/2023Ownership: 0.431%Putnam Investments LLCBought 5,739 shares on 5/22/2023Ownership: 0.054%New York State Common Retirement FundBought 6,447 shares on 5/18/2023Ownership: 0.828%JPMorgan Chase & Co.Bought 8,930 shares on 5/18/2023Ownership: 0.166%View All Insider TransactionsView All Institutional Transactions CSTL Stock - Frequently Asked Questions Should I buy or sell Castle Biosciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Castle Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CSTL shares. View CSTL analyst ratings or view top-rated stocks. What is Castle Biosciences' stock price forecast for 2023? 4 equities research analysts have issued 12-month price targets for Castle Biosciences' stock. Their CSTL share price forecasts range from $25.00 to $54.00. On average, they predict the company's share price to reach $40.57 in the next year. This suggests a possible upside of 237.5% from the stock's current price. View analysts price targets for CSTL or view top-rated stocks among Wall Street analysts. How have CSTL shares performed in 2023? Castle Biosciences' stock was trading at $23.54 at the start of the year. Since then, CSTL stock has decreased by 48.9% and is now trading at $12.02. View the best growth stocks for 2023 here. Are investors shorting Castle Biosciences? Castle Biosciences saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 878,100 shares, a decline of 11.0% from the April 30th total of 986,400 shares. Based on an average daily volume of 145,300 shares, the short-interest ratio is currently 6.0 days. View Castle Biosciences' Short Interest. When is Castle Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our CSTL earnings forecast. How were Castle Biosciences' earnings last quarter? Castle Biosciences, Inc. (NASDAQ:CSTL) issued its earnings results on Wednesday, May, 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.30. The business had revenue of $42.04 million for the quarter, compared to the consensus estimate of $37.63 million. Castle Biosciences had a negative trailing twelve-month return on equity of 17.74% and a negative net margin of 47.11%. What ETFs hold Castle Biosciences' stock? ETFs with the largest weight of Castle Biosciences (NASDAQ:CSTL) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), First Trust Innovation Leaders ETF (ILDR), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), iShares Micro-Cap ETF (IWC), iShares U.S. Healthcare Providers ETF (IHF), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB). What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $173.41 million. What other stocks do shareholders of Castle Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Castle Biosciences investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Block (SQ), DexCom (DXCM), QUALCOMM (QCOM), Teladoc Health (TDOC), Applied Materials (AMAT), Incyte (INCY) and Intel (INTC). When did Castle Biosciences IPO? (CSTL) raised $50 million in an initial public offering on Thursday, July 25th 2019. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. SVB Leerink and Baird served as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Castle Biosciences' stock symbol? Castle Biosciences trades on the NASDAQ under the ticker symbol "CSTL." Who are Castle Biosciences' major shareholders? Castle Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (11.16%), BlackRock Inc. (7.94%), Principal Financial Group Inc. (4.82%), Granahan Investment Management LLC (4.50%), Kornitzer Capital Management Inc. KS (2.43%) and Palisade Capital Management LP (2.16%). Insiders that own company stock include Adam Jay Sussman, Bernhard E Spiess, Bernhard E Spiess, Daniel Bradbury, David S Kabakoff, Derek J Maetzold, Derek J Maetzold, Frank Stokes, Jeffrey E Eberwein, Joseph C Cook III, Kristen M Oelschlager, Mara G Aspinall, Tiffany Olson and Tobin W Juvenal. View institutional ownership trends. How do I buy shares of Castle Biosciences? Shares of CSTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Castle Biosciences' stock price today? One share of CSTL stock can currently be purchased for approximately $12.02. How much money does Castle Biosciences make? Castle Biosciences (NASDAQ:CSTL) has a market capitalization of $320.81 million and generates $137.04 million in revenue each year. The company earns $-67,140,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis. How many employees does Castle Biosciences have? The company employs 342 workers across the globe. How can I contact Castle Biosciences? Castle Biosciences' mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The official website for the company is castlebiosciences.com. The company can be reached via phone at (866) 788-9007 or via email at ir@castlebiosciences.com. This page (NASDAQ:CSTL) was last updated on 6/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.